| Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227 JR Brahmer, JS Lee, TE Ciuleanu, R Bernabe Caro, M Nishio, L Urban, ... Journal of Clinical Oncology 41 (6), 1200-1212, 2023 | 128 | 2023 |
| Assessment of patient-reported outcome instruments to assess chronic low back pain A Ramasamy, ML Martin, SI Blum, H Liedgens, C Argoff, R Freynhagen, ... Pain Medicine 18 (6), 1098-1110, 2017 | 68 | 2017 |
| Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD PY Andrew, A Guérin, DP de Leon, K Ramakrishnan, EQ Wu, M Mocarski, ... Respiratory medicine 105 (12), 1861-1871, 2011 | 66 | 2011 |
| Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label … D Cella, RJ Motzer, C Suarez, SI Blum, F Ejzykowicz, M Hamilton, ... The Lancet Oncology 23 (2), 292-303, 2022 | 62 | 2022 |
| Burden of illness of diabetic peripheral neuropathic pain: a qualitative study M Brod, B Pohlman, SI Blum, A Ramasamy, R Carson The patient-patient-centered outcomes research 8, 339-348, 2015 | 58 | 2015 |
| Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis AP Yu, H Yang, EQ Wu, J Setyawan, M Mocarski, S Blum Journal of Medical Economics 14 (3), 315-323, 2011 | 49 | 2011 |
| First-line nivolumab plus ipilimumab versus chemotherapy in advanced NSCLC with 1% or greater tumor PD-L1 expression: patient-reported outcomes from CheckMate 227 Part 1 M Reck, TE Ciuleanu, JS Lee, M Schenker, C Audigier-Valette, ... Journal of Thoracic Oncology 16 (4), 665-676, 2021 | 32 | 2021 |
| Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis JE Signorovitch, TM Samuelson, K Ramakrishnan, M Marynchenko, ... Current medical research and opinion 28 (4), 591-599, 2012 | 26 | 2012 |
| Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients … EQ Wu, AP Yu, V Lauzon, K Ramakrishnan, M Marynchenko, ... Annals of Pharmacotherapy 45 (4), 441-451, 2011 | 26 | 2011 |
| Symptoms and impacts in anemia of chronic kidney disease SD Mathias, SI Blum, V Sikirica, KL Johansen, HH Colwell, T Okoro Journal of Patient-Reported Outcomes 4, 1-10, 2020 | 25 | 2020 |
| Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: Part 1—the Patient Assessment for Low Back Pain-Symptoms (PAL-S) ML Martin, SI Blum, H Liedgens, DM Bushnell, KP McCarrier, NV Hatley, ... Pain 159 (6), 1045-1055, 2018 | 23 | 2018 |
| Development and validation of the Diabetic Peripheral Neuropathic Pain Impact (DPNPI) measure, a patient-reported outcome measure M Brod, SI Blum, DM Bushnell, A Ramasamy Quality of Life Research 24, 3001-3014, 2015 | 20 | 2015 |
| CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in … J Edeline, T Yau, JW Park, M Kudo, KH Han, P Mathurin, P Merle, RS Finn, ... Journal of Clinical Oncology 38 (4_suppl), 483-483, 2020 | 19 | 2020 |
| Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: the CheckMate 9ER trial. D Cella, TK Choueiri, SI Blum, F Ejzykowicz, M Hamilton, J Zhang, ... Journal of Clinical Oncology 39 (6_suppl), 285-285, 2021 | 18 | 2021 |
| Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder SI Blum, S Tourkodimitris, A Ruth Journal of affective disorders 170, 230-236, 2015 | 14 | 2015 |
| Scale development with small samples: A new application of longitudinal item response theory CR Houts, R Morlock, SI Blum, MC Edwards, RJ Wirth Quality of Life Research 27, 1721-1734, 2018 | 13 | 2018 |
| Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer … JR Brahmer, JS Lee, TE Ciuleanu, R Bernabe Caro, M Nishio, L Urban, ... Journal of Clinical Oncology 40 (17_suppl), LBA9025-LBA9025, 2022 | 11 | 2022 |
| Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced … J Chang, YL Wu, S Lu, J Wang, T Mok, L Zhang, J Feng, L Wu, HY Tu, ... Lung cancer 165, 71-81, 2022 | 11 | 2022 |
| Development and adaptation of patient-reported outcome measures for patients who experience itch associated with primary biliary cholangitis ML Martin, L Stassek, SI Blum, AV Joshi, D Jones Journal of Patient-Reported Outcomes 3, 1-11, 2019 | 11 | 2019 |
| Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States H Huang, DCA Taylor, RT Carson, P Sarocco, M Friedman, M Munsell, ... Journal of Medical Economics 18 (4), 283-294, 2015 | 10 | 2015 |
